Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Antisense Therapeutics launches groundbreaking study on Long Covid

The goals of the study are to generate new intellectual property around the potential diagnosis and treatment of neurological complications of Long COVID-19 and assess whether ATL1102, an RNA inhibitor being developed by Antisense Therapeutics, could also treat Long COVID-19.


News provided by

Antisense Therapeutics Limited

Mar 07, 2022, 18:00 ET

Share this article

Share toX

Share this article

Share toX

Antisense Therapeutics
Antisense Therapeutics

NEW YORK, March 7, 2022 /PRNewswire-PRWeb/ -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] has launched a study that could deliver comprehensive data about Long COVID-19 as early as mid 2022. It is the world's first study of up to 7,000 plasma proteins in Long COVID-19 patients.

As previously announced, the Australian publicly listed biotechnology company is collaborating with Dr. Igor Koralnik on the study. A leading researcher at the Northwestern Memorial Hospital Neuro COVID-19 clinic in Chicago, Illinois, Dr. Koralnik has published on Long COVID-19 in peer reviewed journals. He has treated over a thousand patients with the disease, which is reported to have affected about 30% of people post COVID-19, or as many as 24 million people in the United States.

“Patients with Long COVID-19 show significantly lower scores than the normal population on processing speed, attention, and working memory. This collaboration is an important step towards understanding Long Neuro COVID-19 and the potential for interventional treatment.”- Dr. Igor Koralnik

Post this

The goals of the study are to:

1. Generate new intellectual property around the potential diagnosis and treatment of neurological complications of Long COVID-19.

2. Assess whether ATL1102, an RNA inhibitor being developed by Antisense Therapeutics to treat a rare neuromuscular disease, could also treat Long COVID-19.

"COVID-19 is causing significant long-term cognitive and fatigue complications," said Dr. Koralnik, who has treated over a thousand patients with the disease and has been published in peer reviewed journals. "Patients with Long COVID-19 show significantly lower scores than the normal population on processing speed, attention, and working memory. This collaboration is an important step towards understanding Long Neuro COVID-19 and the potential for interventional treatment."

Antisense Therapeutics will leverage its experience with SomaScan®, a proprietary platform for testing proteins on a large scale developed by Somalogic in Boulder, Colorado. Antisense previously used SomaScan® to test ATL1102, which is showing highly promising clinical results in patients with Duchenne muscular dystrophy (DMD), a rare and fatal muscle wasting disease where muscle inflammation leads to fibrosis and death of muscle tissue.

ATL1102 has also shown biologic activity in patients with Multiple Sclerosis (MS), an autoimmune disease. There may be a link between Long Neuro Covid and abnormal inflammatory responses; it may even share some of the same virus specific pathophysiological changes as other viral infections including Epstein-Barr Virus (EBV) and chronic fatigue syndrome.

Indeed, patients who had COVID-19 while also infected with EBV – which increases the risk of autoimmune diseases like MS and associated adverse neurological manifestations – had an increased risk of memory loss. This study will look for blood disease markers to help determine if ATL1102 could be used to treat Long Neuro COVID-19.

"We want to capitalize on our deep understanding and experience in inflammatory and immune disease," said Dr. George Tachas, Director of Drug Discovery at Antisense Therapeutics. "Our goal is to identify new ways to better treat a disease that is negatively impacting the lives of millions of people around the world."

Under the collaboration, Dr. Koralnik will provide existing blood samples that have already been collected from patients with Long COVID-19. Some of the samples have shown blood immune cell changes in patients where there were neurological symptoms. Somalogic's SomaScan® will be used to generate new data from these samples on up to 7,000 protein changes.

The data will then be analyzed to identify any proteins significantly affected in the blood of convalescent Long COVID-19 patients with no persistent symptoms and Long Neuro COVID-19 patients compared to healthy subjects to identify the proteins that are modulated in Long Neuro COVID-19 disease pathology. This will help determine whether Long Neuro COVID-19 could be treated with ATL1102 or other similar treatments.

The first results of the testing are anticipated in mid-2022. Using existing clinical samples and SomaScan® will save both the time and cost of completing a traditional experimental study and will make Antisense Therapeutics the first to generate the broadest search of plasma proteins on Long Neuro COVID-19.

About Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc., an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis.

About ATL1102- ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease. ATL1102 has also shown to be very effective in reducing inflammatory brain lesions in patients with MS (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788) and recently delivered highly promising clinical results in patients with Duchenne muscular dystrophy (DMD) a rare and fatal muscle wasting disease where inflammation in the muscle leads to fibrosis and death of muscle tissue

Contacts:

Antisense Therapeutics
Mark Diamond                            
Managing Director                    
+61 (0)3 9827 8999                 
http://www.antisense.com.au         

Investment Enquiries
Gennadi Koutchin
XEC Partners
1300 932 037
[email protected]

US/European IR & PR
Laine Yonker/Joe Green
Edison Investor Relations
+1 646-653-7035
[email protected]

Antisense Therapeutics Forward-Looking Statements:

This press release contains forward-looking statements regarding the Company's business & the therapeutic & commercial potential of its technologies & products in development including ATL1102 for Duchenne muscular dystrophy. Any statement describing the Company's goals, expectations, intentions or beliefs is a forward-looking statement & should be considered an at-risk statement. Such statements are subject to certain risks & uncertainties, particularly those risks or uncertainties inherent in the process of developing technology & in the process of discovering, developing & commercializing drugs that can be proven to be safe & effective for use as human therapeutics, & in the endeavor of building a business around such products & services. Actual results could differ materially from those discussed in this press release. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the Antisense Therapeutics Limited Annual Report for the year ended 30 June 2021, which is available from the Company or at http://www.antisense.com.au.

Media Contact

Ari Zoldan, Quantum Media Group, +1 9176808765, [email protected]

SOURCE Antisense Therapeutics Limited

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.